Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
about
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myelomaReelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin β1 signaling.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.MGUS to myeloma: a mysterious gammopathy of underexplored significance.Targeting cancer-related inflammation in the era of immunotherapy.Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells.Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.Multiple myelomaNovel Strategies for Peptide-Based Vaccines in Hematological MalignanciesMechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
P2860
Q36270127-E717C810-D67B-4100-A9F8-F505FF593744Q38694656-F67DFA24-1845-4BDA-B3C7-7D64772A82CFQ38932298-1061C202-7A5B-42EC-B958-33288DB8FA01Q38979865-4C8C99B0-A782-498D-8FA3-935246136CC5Q39044981-FF2BB717-127C-4F23-97D1-A5F6BC73809EQ41620482-A927EB85-4052-409B-8FF9-8FDD3A673809Q41785517-56B0CADD-D07C-4180-9F2C-E5C6F059BDA9Q41895213-11F1A678-F611-4F01-8E7B-535117541F50Q47565827-FBAAFED7-7961-4B23-BEC6-6AC4D561A578Q48364794-0C25691F-85DD-4DCA-9B10-0173EE8C05BBQ50026815-D9890419-764E-408B-83B5-E77448EF4821Q52777089-7B9C9281-A4F8-4E22-B20B-F8CC4BC8F004Q55462347-DB189AA0-10DF-4940-AC00-CAD33C675151Q56657250-55165C00-31C7-481F-B619-8DCAF6456ABBQ57486479-A021FEC1-7A6A-4F09-B376-FC6CDF12E19FQ59136966-858482C3-14B6-4A51-8D73-6F7E4FD9DE1D
P2860
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Immune responses in multiple m ...... potential of immunotherapies.
@en
type
label
Immune responses in multiple m ...... potential of immunotherapies.
@en
prefLabel
Immune responses in multiple m ...... potential of immunotherapies.
@en
P2860
P50
P1476
Immune responses in multiple m ...... potential of immunotherapies.
@en
P2093
Camille Guillerey
Slavica Vuckovic
P2860
P2888
P304
P356
10.1007/S00018-016-2135-Z
P577
2016-01-22T00:00:00Z